

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application:

Listing of Claims:

1. (Previously Presented) A method for determining whether a test compound is capable of affecting cell division, said method comprising:

a) contacting said test compound with isolated estrogen receptor beta (ER β) and mitosis arrest deficient 2 (MAD2), or a binding fragment thereof, under conditions in which ER β and MAD2, or a fragment thereof, have formed, or are able to form, a complex; and

b) determining whether said test compound affects said ER β /MAD2 complex or complex formation, as an indication that said test compound is capable of affecting cell division.

2. (Previously Presented) The method of claim 1, wherein said MAD2 is encoded by a nucleic acid molecule comprising the sequence set forth in SEQ ID NO: 3.

3. (Original) The method of claim 1, wherein said determining is done *in vitro*.

4. (Withdrawn) The method of claim 1, wherein said determining is done *in vivo*.

5. (Withdrawn) The method of claim 1, wherein said determining is done using a yeast two-hybrid system.

6. (Previously Presented) The method of claim 1, wherein said ER β additionally comprises glutathione-S-transferase (GST) and said complex or complex formation is determined using a GST-fusion protein interaction assay.

7. (Withdrawn) The method of claim 1, wherein said determining is done by fluorescence spectroscopy.

8. (Withdrawn) The method of claim 1, wherein said determining is done by biomolecular interaction analysis.

Claims 9-12: Cancelled.